Cancer Genetics and Epigenetics 2024, Vol.12, No.5, 234-253 http://medscipublisher.com/index.php/cge 250 Lenz H.J., Van Cutsem E., Luisa Limon M., Wong K.Y.M., Hendlisz A., Aglietta M., García-Alfonso P., Neyns B., Luppi G., Cardin D.B., Dragovich T., Shah U., Abdullaev S., Gricar J., Ledeine J.M., Michael James Overman M.J., , and Lonardi S., 2022, First-Line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II checkmate 142 study, Journal of Clinical Oncology, 40(2): 161-170. https://doi.org/10.1200/JCO.21.01015 Liang Z.Y., Cui X.Y., Yang L.Q., Hu Q., Li D.Y., Zhang X.F., Han L., Shi S.W., Shen Y.R., Zhao W.J., Ju Q., Deng X.W., Yan Wu Y., and Sheng W., 2021, Co-assembled nanocomplexes of peptide neoantigen Adpgk and Toll-like receptor 9 agonist CpG ODN for efficient colorectal cancer immunotherapy, International Journal of Pharmaceutics, 608: 121091. https://doi.org/10.1016/j.ijpharm.2021.121091 Li J.X., Hu H.B., Qin G., Bai F., Wu X.R., Ke H.X., Zhang J.W., Xie Y.Q., Wu Z.H., Fu Y., Zheng H.B., Gong L.L., Xie Z., and Deng Y.Z., 2024, Biomarkers of pathologic complete response to neoadjuvant immunotherapy in mismatch repair-deficient colorectal cancer, Clinical Cancer Research, 30(2): 368-378. Ma S.C., Chen R., Duan L., Li C.M., Yang T.N., Wang J.K., and Zhao D., 2023, Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study, Journal of Gastrointestinal Oncology, 14(2): 1052-1063. https://doi.org/10.21037/jgo-23-108 Ma X.T., Dong L., Liu X., Ou K., and Yang L., 2022, POLE/POLD1 mutation and tumor immunotherapy, Journal of Experimental & Clinical Cancer Research, 41(1): 216. https://doi.org/10.1186/s13046-022-02422-1 PMID: 35780178 PMCID: PMC9250176 Marabelle A., Fakih M., Lopez J., Shah M., Shapira-Frommer R., Nakagawa K., Chung H.C., Kindler H.L., Lopez-Martin J.A., Jr Miller W.H., Italiano A., Kao S., Piha-Paul, S.A., Delord J.P., McWilliams R.R., Fabrizio D.A., Aurora-Garg D., Xu L., Fan JinF., Norwood K., and Bang Y.J., 2020, Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study, The Lancet Oncology, 21: 1353-1365. https://doi.org/10.1016/S1470-2045(20)30445-9 Marin N.D., Becker-Hapak M., Song W.M., Alayo Q.A., Marsala L., Sonnek N., Berrien-Elliott M.M., Foster M., Foltz J.A., Tran J., Wong P., Cubitt C.C., Pence P., Hwang K., Zhou A.Y., Jacobs M.T., Schappe T., Russler-Germain D.A., Fields R.C., Ciorba M.A., and Fehniger T.A., 2024, Memory-like differentiation enhances NK cell responses against colorectal cancer, Oncoimmunology 13(1): 2348254. https://doi.org/10.1080/2162402X.2024.2348254 Marques A., Cavaco P., Torre C., Sepodes B., and Rocha J., 2024, Tumor mutational burden in colorectal cancer: implications for treatment, Critical Reviews in oncology/Hematology, 197: 104342. https://doi.org/10.1016/j.critrevonc.2024.104342 Martinelli E., Martini G., Famiglietti V., Troiani T., Napolitano S., Pietrantonio F., Ciardiello D., Terminiello M., Borrelli C., Vitiello P.P., De Braud F., Morano F., Avallone A., NormannoN., Nappi A., MaielloE., Latiano T., Falcone A., Cremolini C., Rossini D., Santabarbara G., Pinto C., Santini D., Cardone C., Zanaletti N., Di Liello A., Renato D., Esposito L., Marrone F., and Ciardiello F., 2021, Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial, JAMA Oncology, 7(10): 1529-1535. https://doi.org/10.1001/jamaoncol.2021.2915 PMID: 34382998 PMCID: PMC8531995 Middleton G., Liu W., Savage J., Bridgewater J.A., Ross P., Saunders M.P., Plummer R., Clive S., Coyle V., Thomas A., Taniere P., and Billingham L., 2022, 426P Assessing nivolumab in class II expressing microsatellite stable (pMMR) colorectal cancer (CRC): Results of the ANICCA-Class II trial, Annals of Oncology, 33(7): S729-S730. https://doi.org/10.1016/j.annonc.2022.07.564 Monjazeb A.M., Giobbie-Hurder A., Lako A., Thrash E.M., Brennick R.C., Kao K.Z., Manuszak C., Gentzler R.D., Tesfaye A., Jabbour S.K., Alese O.B., Rahma O.E., Cleary J.M., Elad Sharon E., Mamon H.J., May Cho M., Streicher H., Chen H.X., Ahmed M.M., Mariño-Enríquez A., Kim-Schulze S., Sacha Gnjatic S., Maverakis E., Marusina A.I., Merleev A.A., Severgnini M., Pfaff K.L., Lindsay J., Weirather J.L., Ranasinghe S., Spektor A., Rodig S.J., Hodi F.S., and Schoenfeld J.D., 2021, A randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation for patients with metastatic colorectal cancer, Clinical Cancer Research, 27(9): 2470-2480. https://doi.org/10.1158/1078-0432.CCR-20-4632 Mullard A., 2024, FDA approves first tumour-infiltrating lymphocyte, (TIL) therapy, bolstering hopes for cell therapies in solid cancers, Nature Reviews Drug Discovery, 23: 238. https://doi.org/10.1038/d41573-024-00035-1 Naciute M., Niemi V., Kemp R.A., and Hook S., 2020, Lipid-encapsulated oral therapeutic peptide vaccines reduce tumour growth in an orthotopic mouse model of colorectal cancer, European Kournal of Pharmaceutics and Biopharmaceutics, 152: 183-192. https://doi.org/10.1016/j.ejpb.2020.04.020 Nixon A.B., Schalper K.A., Jacobs I., Potluri S., Wang I.M., and Fleener C., 2019, Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential? Journal for Immunotherapy of Cancer, 7: 325. https://doi.org/10.1186/s40425-019-0799-2 Omole R.K., Oluwatola O., Akere M.T., Eniafe J., Agboluaje E.O., Daramola O.B., Ayantunji Y.J., Omotade T.I., Torimiro N., Ayilara M.S., and Adeyemi U.L., 2022, Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy, Frontiers in Pharmacology, 13: 1082797.
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==